Robert Silva

2.4k total citations
24 papers, 1.6k citations indexed

About

Robert Silva is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Robert Silva has authored 24 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Psychiatry and Mental health, 4 papers in Pharmacology and 3 papers in Clinical Psychology. Recurrent topics in Robert Silva's work include Bipolar Disorder and Treatment (11 papers), Schizophrenia research and treatment (7 papers) and Electroconvulsive Therapy Studies (6 papers). Robert Silva is often cited by papers focused on Bipolar Disorder and Treatment (11 papers), Schizophrenia research and treatment (7 papers) and Electroconvulsive Therapy Studies (6 papers). Robert Silva collaborates with scholars based in United States, United Kingdom and France. Robert Silva's co-authors include Antony Loebel, Josephine Cucchiaro, Kaushik Sarma, Hans Kröger, Jane Xu, Jay Hsu, James B. Rottman, Debra Phillips, Gary Sachs and Wayne W. Hancock and has published in prestigious journals such as Nature Immunology, American Journal of Psychiatry and European Journal of Immunology.

In The Last Decade

Robert Silva

22 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Silva United States 16 1.0k 337 317 145 134 24 1.6k
Olawale Osuntokun United States 17 578 0.6× 359 1.1× 1.5k 4.8× 100 0.7× 163 1.2× 27 2.5k
Hiroshi Hamakawa Japan 25 578 0.6× 54 0.2× 58 0.2× 198 1.4× 103 0.8× 74 1.7k
Fiona Forrestal United States 10 167 0.2× 178 0.5× 63 0.2× 155 1.1× 105 0.8× 17 1.0k
Kyoko Taniguchi Japan 19 103 0.1× 195 0.6× 105 0.3× 211 1.5× 59 0.4× 48 1.1k
Julian C. Matthews United Kingdom 27 237 0.2× 89 0.3× 59 0.2× 224 1.5× 257 1.9× 113 2.4k
Kimberley Jackson United States 16 265 0.3× 165 0.5× 333 1.1× 197 1.4× 190 1.4× 28 2.1k
Paolo Zanotti‐Fregonara United States 30 224 0.2× 220 0.7× 102 0.3× 370 2.6× 220 1.6× 113 2.8k
Linda Chang United States 16 262 0.3× 245 0.7× 92 0.3× 64 0.4× 89 0.7× 27 2.0k
Susanne Englisch Germany 21 706 0.7× 110 0.3× 111 0.4× 615 4.2× 51 0.4× 46 2.9k
Yoko Ikoma Japan 22 269 0.3× 171 0.5× 43 0.1× 199 1.4× 52 0.4× 95 1.9k

Countries citing papers authored by Robert Silva

Since Specialization
Citations

This map shows the geographic impact of Robert Silva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Silva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Silva more than expected).

Fields of papers citing papers by Robert Silva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Silva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Silva. The network helps show where Robert Silva may publish in the future.

Co-authorship network of co-authors of Robert Silva

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Silva. A scholar is included among the top collaborators of Robert Silva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Silva. Robert Silva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goldstein, Andrew T., Rachel Rubin, Irwin Goldstein, et al.. (2025). Phase 2 randomized study of abobotulinumtoxinA in patients with provoked vestibulodynia: dose-finding results. The Journal of Sexual Medicine. 22(4). 588–596.
2.
DiDomenico, Lawrence A., et al.. (2023). Exploring the Relationship Between Clinical Presentation in Hallux Valgus and Response to AbobotulinumtoxinA Treatment. The Journal of Foot & Ankle Surgery. 62(3). 556–562.
3.
Armstrong, David G., et al.. (2022). Pain Reduction With AbobotulinumtoxinA for the Treatment of Hallux Valgus in Adult Participants: Results of a Randomized and Placebo-Controlled Phase 2 Trial. The Journal of Foot & Ankle Surgery. 62(2). 244–253. 1 indexed citations
4.
Tsai, Joyce, et al.. (2017). Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment. International Journal of Bipolar Disorders. 5(1). 22 indexed citations
5.
Correll, Christoph U., et al.. (2016). Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectrums. 21(5). 393–402. 30 indexed citations
6.
Targum, Steven D., Trisha Suppes, J. Cara Pendergrass, et al.. (2016). Major depressive disorder with subthreshold hypomania (mixed features): Clinical characteristics of patients entered in a multiregional, placebo-controlled study. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 68. 9–14. 21 indexed citations
7.
Loebel, Antony, Robert Silva, Robert Goldman, et al.. (2016). Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia. The Journal of Clinical Psychiatry. 77(12). 1672–1680. 31 indexed citations
8.
Ketter, Terence A., Kaushik Sarma, Robert Silva, et al.. (2016). LURASIDONE IN THE LONG‐TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24‐WEEK OPEN‐LABEL EXTENSION STUDY. Depression and Anxiety. 33(5). 424–434. 37 indexed citations
9.
Findling, Robert L., et al.. (2015). Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders. Clinical Therapeutics. 37(12). 2788–2797. 32 indexed citations
10.
Loebel, Antony, Matthew Brams, Robert Goldman, et al.. (2015). Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. Journal of Autism and Developmental Disorders. 46(4). 1153–1163. 64 indexed citations
11.
Suppes, Trisha, Robert Silva, Josephine Cucchiaro, et al.. (2015). Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry. 173(4). 400–407. 104 indexed citations
12.
Nasrallah, Henry A., Robert Silva, Debra Phillips, et al.. (2013). Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. Journal of Psychiatric Research. 47(5). 670–677. 119 indexed citations
13.
Loebel, Antony, Josephine Cucchiaro, Robert Silva, et al.. (2013). Lurasidone as Adjunctive Therapy With Lithium or Valproate for the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry. 171(2). 169–177. 163 indexed citations
14.
Citrome, Leslie, Josephine Cucchiaro, Kaushik Sarma, et al.. (2012). Long-term safety and tolerability of lurasidone in schizophrenia. International Clinical Psychopharmacology. 27(3). 165–176. 99 indexed citations
15.
Cucchiaro, Josephine, Robert Silva, Masaaki Ogasa, et al.. (2010). LURASIDONE IN THE TREATMENT OF ACUTE SCHIZOPHRENIA: RESULTS OF THE DOUBLE-BLIND, PLACEBO-CONTROLLED PEARL 2 TRIAL. Schizophrenia Research. 117(2-3). 493–493. 4 indexed citations
16.
Loebel, Antony, Josephine Cucchiaro, Robert Silva, et al.. (2010). EFFICACY OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A POOLED ANALYSIS BASED ON A 5-FACTOR MODEL OF SCHIZOPHRENIA. Schizophrenia Research. 117(2-3). 267–267. 6 indexed citations
17.
Rottman, James B., Tammy Smith, James R. Tonra, et al.. (2001). The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nature Immunology. 2(7). 605–611. 226 indexed citations
18.
Rottman, James B., et al.. (2000). Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. European Journal of Immunology. 30(8). 2372–2377. 158 indexed citations
19.
Price, W.W., Fred C. Schweppe, E.M. Gulachenski, & Robert Silva. (1974). Maximum likelihood identification of power system dynamic equivalents. 579–586. 13 indexed citations
20.
Silva, Robert, James W. Harris, M. Nurmia, K. Eskola, & A. Ghiorso. (1970). Chemical separation of rutherfordium. Inorganic and Nuclear Chemistry Letters. 6(12). 871–877. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olawale Osuntokun Breakdown of academic impact, for papers by Hiroshi Hamakawa Breakdown of academic impact, for papers by Fiona Forrestal Breakdown of academic impact, for papers by Kyoko Taniguchi Breakdown of academic impact, for papers by Julian C. Matthews Breakdown of academic impact, for papers by Kimberley Jackson Breakdown of academic impact, for papers by Paolo Zanotti‐Fregonara Breakdown of academic impact, for papers by Linda Chang Breakdown of academic impact, for papers by Susanne Englisch Breakdown of academic impact, for papers by Yoko Ikoma
Rankless by CCL
2026